BIOA Quote, Financials, Valuation and Earnings

Iovance Biotherapeutics, Inc. has a net margin of -842.85% compared to BioAge Labs, Inc.'s net margin of -82.92%. BioAge Labs, Inc.'s return on equity of -27.22% beat Iovance Biotherapeutics, Inc.'s return on equity of -54.64%.

BioAge Labs, Inc. has a consensus price target of $53.33, signalling upside risk potential of 204.76%. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 162.39%. Given that BioAge Labs, Inc. has higher upside potential than Iovance Biotherapeutics, Inc., analysts believe BioAge Labs, Inc. is more attractive than Iovance Biotherapeutics, Inc..

BioAge Labs, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.765, suggesting its less volatile than the S&P 500 by 23.49%.

BioAge Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioAge Labs, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

BioAge Labs, Inc. quarterly revenues are $3.1M, which are smaller than Iovance Biotherapeutics, Inc. quarterly revenues of $86.7M. BioAge Labs, Inc.'s net income of -$25.9M is higher than Iovance Biotherapeutics, Inc.'s net income of -$71.9M. Notably, BioAge Labs, Inc.'s price-to-earnings ratio is -- while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioAge Labs, Inc. is 69.87x versus 4.62x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -842.85% compared to BioAge Labs, Inc.'s net margin of 34.4%. BioAge Labs, Inc.'s return on equity of -27.22% beat Eli Lilly & Co.'s return on equity of 104.39%.

BioAge Labs, Inc. has a consensus price target of $53.33, signalling upside risk potential of 204.76%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,209.21 which suggests that it could grow by 29.25%. Given that BioAge Labs, Inc. has higher upside potential than Eli Lilly & Co., analysts believe BioAge Labs, Inc. is more attractive than Eli Lilly & Co..

BioAge Labs, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.506, suggesting its less volatile than the S&P 500 by 49.45%.

BioAge Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.68% to investors and pays a quarterly dividend of $1.73 per share. BioAge Labs, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

BioAge Labs, Inc. quarterly revenues are $3.1M, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. BioAge Labs, Inc.'s net income of -$25.9M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, BioAge Labs, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 40.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioAge Labs, Inc. is 69.87x versus 12.82x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Protokinetix, Inc. has a net margin of -842.85% compared to BioAge Labs, Inc.'s net margin of --. BioAge Labs, Inc.'s return on equity of -27.22% beat Protokinetix, Inc.'s return on equity of -111.59%.

BioAge Labs, Inc. has a consensus price target of $53.33, signalling upside risk potential of 204.76%. On the other hand Protokinetix, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that BioAge Labs, Inc. has higher upside potential than Protokinetix, Inc., analysts believe BioAge Labs, Inc. is more attractive than Protokinetix, Inc..

BioAge Labs, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Protokinetix, Inc. has a beta of 0.655, suggesting its less volatile than the S&P 500 by 34.475%.

BioAge Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protokinetix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioAge Labs, Inc. pays -- of its earnings as a dividend. Protokinetix, Inc. pays out -- of its earnings as a dividend.

BioAge Labs, Inc. quarterly revenues are $3.1M, which are larger than Protokinetix, Inc. quarterly revenues of --. BioAge Labs, Inc.'s net income of -$25.9M is lower than Protokinetix, Inc.'s net income of -$84.9K. Notably, BioAge Labs, Inc.'s price-to-earnings ratio is -- while Protokinetix, Inc.'s PE ratio is 23.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioAge Labs, Inc. is 69.87x versus -- for Protokinetix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -842.85% compared to BioAge Labs, Inc.'s net margin of -417.92%. BioAge Labs, Inc.'s return on equity of -27.22% beat Plus Therapeutics, Inc.'s return on equity of --.

BioAge Labs, Inc. has a consensus price target of $53.33, signalling upside risk potential of 204.76%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $146.88 which suggests that it could grow by 4025.7%. Given that Plus Therapeutics, Inc. has higher upside potential than BioAge Labs, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than BioAge Labs, Inc..

BioAge Labs, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 1.025, suggesting its more volatile than the S&P 500 by 2.509%.

BioAge Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioAge Labs, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

BioAge Labs, Inc. quarterly revenues are $3.1M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. BioAge Labs, Inc.'s net income of -$25.9M is lower than Plus Therapeutics, Inc.'s net income of -$5.7M. Notably, BioAge Labs, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioAge Labs, Inc. is 69.87x versus 3.21x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.